Back to Search
Start Over
Phase II of doxorubicin/taxol in metastatic breast cancer. Argentine Multicenter Taxol Group.
- Source :
-
Breast cancer research and treatment [Breast Cancer Res Treat] 1999 May; Vol. 55 (1), pp. 91-6. - Publication Year :
- 1999
-
Abstract
- Purpose: To assess the response rate, survival, and toxicity of Taxol (paclitaxel) as 1-h infusion plus doxorubicin as first-line treatment for patients with metastatic breast cancer (MBC).<br />Patients and Methods: Seventy-six patients with untreated MBC were recruited. All of them had measurable disease and were evaluable for toxicity. Fifty-five percent of the patients had visceral involvement. The dose of doxorubicin was fixed at 50 mg/m2 as a short intravenous infusion, followed by 200 mg/m2 of Taxol as a 1-h intravenous infusion. Doxorubicin was administered during the first seven cycles, continuing with Taxol only up to a maximum of ten cycles.<br />Results: Neutropenia was the most important toxicity: 30% grade 3 and 18% grade 4. Only 2 patients showed a decrease in the left ventricular ejection fraction (LVEF) which caused discontinuing the treatment. No clinical congestive heart failure (CHF) was observed. Seventy-four patients were eligible for response evaluation: 10 (14%) achieved complete response (CR) and 46 (62%) achieved partial response (PR). The mean duration of response was 13.47+/-1.35 months (95% confidence interval (CI): 10.82; 16.12) and the mean survival was 21.50+/-1.42 months (95% CI: 18.72; 24.29).<br />Conclusion: The overall response (OR) rate was 76%. No CHF was assessed and 2 patients stopped treatment due to LVEF decrease. Although doxorubicin 50 mg/m2 followed by Taxol 200 mg/m2 in 1-h intravenous infusion presents a toxicity profile which demands a close follow-up, it represents a convenient outpatient schedule with similar activity rate compared to longer Taxol infusions.
- Subjects :
- Adult
Aged
Antineoplastic Combined Chemotherapy Protocols adverse effects
Argentina
Breast Neoplasms mortality
Breast Neoplasms pathology
Dose-Response Relationship, Drug
Doxorubicin administration & dosage
Doxorubicin adverse effects
Drug Administration Schedule
Female
Humans
Middle Aged
Neoplasm Metastasis
Neutropenia chemically induced
Paclitaxel administration & dosage
Paclitaxel adverse effects
Stroke Volume drug effects
Survival Analysis
Treatment Outcome
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Breast Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 0167-6806
- Volume :
- 55
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Breast cancer research and treatment
- Publication Type :
- Academic Journal
- Accession number :
- 10472783
- Full Text :
- https://doi.org/10.1023/a:1006194909859